Abiopharma

BIO-TECHNE CORP (TECH)

Symbol	TECH
Name	BIO-TECHNE CORP
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Biological Products (No Diagnostic Substances)
Address	614 MCKINLEY PLACE N.E., MINNEAPOLIS, Minnesota, 55413, United States
Telephone	+1 612 379-8854
Fax	—
Email	—
Website	https://www.bio-techne.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0000842023
Description	Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%. Additional info from NASDAQ: Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

2026-07-08 10:30

Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio

2026-06-29 20:21

Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH

2026-06-26 18:24

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)

2026-06-25 17:46

New Form DEFA14A - BIO-TECHNE Corp Filed: 2026-06-25 AccNo: 0001999371-26-013514 Size: 200 KB

2026-06-25 14:00

Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders

2026-06-25 12:21

(19% Negative) BIO-TECHNE CORP (TECH) Announces Business Combination

2026-06-25 11:48

TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders

2026-06-25 10:10

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

2026-06-25 10:10

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

2026-06-04 20:28

Crouse Steven C. 🟡 adjusted position in 126.8K shares (16 derivative) of BIO-TECHNE Corp (TECH) at $120.46 ($9.3M) Transaction Date: Jun 02, 2026 | Filing ID: 000096

No clinical trials found for this company.

No clinical products found for this company.